Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Home
R&D
Page 52
R&D
Featured posts
Latest
Featured posts
Most popular
7 days popular
By review score
Random
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
FDA orphan drug and rare pediatric disease designations granted to Arbor Biotechnologies’ primary hyperoxaluria type 1 treatment
Relmada Therapeutics acquires potential Tourette syndrome therapy from Asarina Pharma
Vanda Pharmaceuticals and AnaptysBio announce global license agreement for Generalized Pustular Psoriasis treatment
Silence Therapeutics and Hansoh Pharma to develop siRNA therapeutics
19th October 2021
Janssen receives positive CHMP opinion for RYBREVANT® (amivantamab) for treatment of...
18th October 2021
Safety results from large real-world safety study in combined oral contraception...
18th October 2021
Pfizer and BioNTech submit data to EMA for COVID vaccine for...
18th October 2021
Immusoft and Takeda to develop cell therapies for rare neurometabolic disorders
15th October 2021
CureVac to shift focus of COVID-19 vaccine development to second-gen mRNA...
15th October 2021
Advancing access to complex medicines through Strategic Growth
13th October 2021
Irish research centre partners with five major BioPharma companies
4th October 2021
UNION and Innovent collaborate on next-gen PDE4 inhibitor for inflammatory dermatology...
30th September 2021
Syndax and Incyte to develop axatilimab for fibrotic diseases
29th September 2021
1
...
51
52
53
Page 52 of 53
News
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, have announced a collaboration and...
Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData
14th February 2025
The Duchenne muscular dystrophy (DMD) market across the seven major markets (7MM*) is set to grow from $2.3 billion in 2023 to $5.2 billion...
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
13th February 2025
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a...